Developmental Biology

Edited by: Paul Smaglik P. Carmeliet, V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, K. Harpal, C. Eberhardt, C. Declercq, J. Pawling, L. Moons, D. Collen, W. Risau, A. Nagy, "Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele," Nature, 380:435-9, 1996. (Cited in more than 235 papers since publication) Comments by Andras Nagy, senior staff scientist, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, To

Listen with Speechify

0:00

6:00

Edited by: Paul Smaglik
P. Carmeliet, V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, K. Harpal, C. Eberhardt, C. Declercq, J. Pawling, L. Moons, D. Collen, W. Risau, A. Nagy, "Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele," Nature, 380:435-9, 1996. (Cited in more than 235 papers since publication)

Comments by Andras Nagy, senior staff scientist, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto

N. Ferrara, K. Carver-Moore, H. Chen, M. Dowd, L. Lu, K.S. O'Shea, L. Powell-Braxton, K.J. Hillan, M.W. Moore, "Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene," Nature, 380:439-42, 1996. (Cited in more than 215 papers since publication)

Comments by Napoleone Ferrara, staff scientist at the Department of Cardiovascular Research, Molecular Biology, and Bioanalytical Technology, Genentech Inc., South San Francisco, Calif., and Mark W. Moore, founder of Deltagen, San Carlos, Calif.

Two groups. ...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!

Join for free today

Already a member? Login Here